FLUDARABINE AND CYCLOPHOSPHAMIDE CHEMOTHERAPY MET ITS PRIMARY ENDPOINT
(repeating to add coding)
- GENENTECH INC SAYS GLOBAL PHASE III STUDY OF RITUXAN IN COMBINATION WITH
FLUDARABINE AND CYCLOPHOSPHAMIDE CHEMOTHERAPY MET ITS PRIMARY ENDPOINT
tf.TFN-Europe_newsdesk@thomson.com
vs
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|